CN111683682A - 用于预防或治疗伴有眼内血管新生和/或眼内血管通透性亢进的眼科疾病的药物 - Google Patents

用于预防或治疗伴有眼内血管新生和/或眼内血管通透性亢进的眼科疾病的药物 Download PDF

Info

Publication number
CN111683682A
CN111683682A CN201980010708.6A CN201980010708A CN111683682A CN 111683682 A CN111683682 A CN 111683682A CN 201980010708 A CN201980010708 A CN 201980010708A CN 111683682 A CN111683682 A CN 111683682A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
acceptable salt
selective
receptor
intraocular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980010708.6A
Other languages
English (en)
Chinese (zh)
Inventor
原英彰
成宫周
青木友浩
荒森一朗
山本梨绘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Kyoto University NUC
Original Assignee
Astellas Pharma Inc
Kyoto University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc, Kyoto University NUC filed Critical Astellas Pharma Inc
Publication of CN111683682A publication Critical patent/CN111683682A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201980010708.6A 2018-02-02 2019-02-01 用于预防或治疗伴有眼内血管新生和/或眼内血管通透性亢进的眼科疾病的药物 Pending CN111683682A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018-016911 2018-02-02
JP2018016911 2018-02-02
PCT/JP2019/003573 WO2019151470A1 (ja) 2018-02-02 2019-02-01 眼内血管新生及び／又は眼内血管透過性亢進を伴う眼科疾患の予防又は治療のための医薬

Publications (1)

Publication Number Publication Date
CN111683682A true CN111683682A (zh) 2020-09-18

Family

ID=67479734

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980010708.6A Pending CN111683682A (zh) 2018-02-02 2019-02-01 用于预防或治疗伴有眼内血管新生和/或眼内血管通透性亢进的眼科疾病的药物

Country Status (17)

Country Link
US (1) US20210113529A1 (https=)
EP (1) EP3747471A4 (https=)
JP (1) JPWO2019151470A1 (https=)
KR (1) KR20200116953A (https=)
CN (1) CN111683682A (https=)
AU (1) AU2019214265A1 (https=)
BR (1) BR112020015567A2 (https=)
CA (1) CA3089952A1 (https=)
IL (1) IL275603A (https=)
JO (1) JOP20200186A1 (https=)
MA (1) MA53098A (https=)
MX (1) MX2020007948A (https=)
PH (1) PH12020551015A1 (https=)
RU (1) RU2020128700A (https=)
SG (1) SG11202006255UA (https=)
WO (1) WO2019151470A1 (https=)
ZA (1) ZA202004327B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113082031A (zh) * 2021-03-09 2021-07-09 温州医科大学附属眼视光医院 一种多巴胺d1和d2受体非选择性激动剂在作为制备治疗眼部病理性血管新生药物的应用
WO2025077706A1 (zh) * 2023-10-08 2025-04-17 华东师范大学 用于肌病治疗的s1pr4调节剂化合物及其应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021148439A1 (en) * 2020-01-21 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for stimulating cerebrovascular function
WO2021163355A1 (en) * 2020-02-11 2021-08-19 Arena Pharmaceuticals, Inc. Formulations and methods of treating conditions related to the s1p1 receptor
KR20230051154A (ko) * 2020-06-11 2023-04-17 더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 스핑고신-1-포스페이트 수용체 조절제인 핑골리모드 및 이의 유도체를 이용한 근시의 예방 및 치료를 위한 방법 및 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005002559A2 (en) * 2003-06-24 2005-01-13 University Of Connecticut Methods of inhibiting vascular permeability and apoptosis
CN101784535A (zh) * 2007-06-15 2010-07-21 生物计划公司 作为s1p1受体激动剂的新的二羧酸衍生物
US20160113917A1 (en) * 2013-04-26 2016-04-28 Kyoto University Medicinal composition for inhibiting formation and/or enlargement of cerebral aneurysm or shrinking same

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
US8022225B2 (en) 2004-08-04 2011-09-20 Taisho Pharmaceutical Co., Ltd Triazole derivative
GB0504544D0 (en) 2005-03-04 2005-04-13 Novartis Ag Organic compounds
EP1988083B1 (en) 2006-02-03 2014-04-02 Taisho Pharmaceutical Co., Ltd. Triazole derivative
JP5218737B2 (ja) 2006-02-06 2013-06-26 大正製薬株式会社 スフィンゴシン−１−リン酸結合阻害物質
MX2008012738A (es) * 2006-04-03 2009-02-06 Astellas Pharma Inc Heterocompuesto.
EP2083862A4 (en) 2006-10-27 2012-09-19 Lpath Inc COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES AND DISORDERS
CA2666709A1 (en) 2006-11-10 2008-05-29 Genentech, Inc. Method for treating age-related macular degeneration
DK2177512T3 (da) 2007-08-01 2012-06-18 Taisho Pharmaceutical Co Ltd S1P1-bindingshæmmer
US8193378B2 (en) 2008-12-05 2012-06-05 Astellas Pharma Inc. 2H-chromene compound and derivative thereof
CA2778611A1 (en) 2009-10-23 2011-04-28 Allergan, Inc. Coumarin compounds as receptor modulators with therapeutic utility
JP5939158B2 (ja) 2009-11-24 2016-06-22 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 治療的有用性を有する受容体調節物質としての新規化合物
CN102711756A (zh) 2010-01-14 2012-10-03 株式会社三和化学研究所 用于预防或治疗伴有眼内血管生成及/或眼内血管通透性增高的疾病的药物
US8273776B2 (en) 2010-04-16 2012-09-25 Allergan, Inc Biphenyl oxadiazole derivatives as sphingosine-1-phosphate receptors modulators
EP2643303A1 (en) 2010-11-24 2013-10-02 Allergan, Inc. Modulators of s1p receptors
KR20130133216A (ko) 2010-11-24 2013-12-06 알러간, 인코포레이티드 S1p 수용체의 신규한 인돌 조절제
JP2014508106A (ja) 2010-12-03 2014-04-03 アラーガン インコーポレイテッド スフィンゴシン−１−リン酸−１受容体モジュレーターとしてのアルキンおよびアルケン誘導体
WO2012105610A1 (ja) 2011-02-02 2012-08-09 公立大学法人名古屋市立大学 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬
AU2012242807A1 (en) 2011-04-14 2013-11-07 Allergan, Inc. Phenyl bicyclic methyl azetidine derivatives as sphingosine-1 phosphate receptors modulators
SG194209A1 (en) 2011-04-18 2013-11-29 Allergan Inc Substituted bicyclic methyl amine derivatives as sphingosine-1-phosphate receptors modulators
US9000016B2 (en) 2012-11-05 2015-04-07 Allergan, Inc. 1,3,4-Oxadiazoles-2-thio derivatives as sphingosine-1 phosphate receptors modulators
US8735433B1 (en) 2012-11-14 2014-05-27 Allergan, Inc. Aryl oxadiazole derivatives as sphingosine 1-phosphate (S1P) receptor modulators
WO2014130565A1 (en) 2013-02-20 2014-08-28 Allergan, Inc. Substituted diaryl azetidine derivatives as sphingosine receptor modulators
JP2018016911A (ja) 2016-07-28 2018-02-01 村田機械株式会社 解析装置

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005002559A2 (en) * 2003-06-24 2005-01-13 University Of Connecticut Methods of inhibiting vascular permeability and apoptosis
CN101784535A (zh) * 2007-06-15 2010-07-21 生物计划公司 作为s1p1受体激动剂的新的二羧酸衍生物
US20160113917A1 (en) * 2013-04-26 2016-04-28 Kyoto University Medicinal composition for inhibiting formation and/or enlargement of cerebral aneurysm or shrinking same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LAURENT PEYRIN-BIROULET ETAL.: "Modulation of sphingosine-1-phosphate in inflammatory bowel disease", 《AUTOIMMUNITY REVIEWS》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113082031A (zh) * 2021-03-09 2021-07-09 温州医科大学附属眼视光医院 一种多巴胺d1和d2受体非选择性激动剂在作为制备治疗眼部病理性血管新生药物的应用
WO2025077706A1 (zh) * 2023-10-08 2025-04-17 华东师范大学 用于肌病治疗的s1pr4调节剂化合物及其应用

Also Published As

Publication number Publication date
IL275603A (en) 2020-08-31
MA53098A (fr) 2021-05-12
US20210113529A1 (en) 2021-04-22
RU2020128700A3 (https=) 2022-03-02
JOP20200186A1 (ar) 2020-07-29
JPWO2019151470A1 (ja) 2021-02-25
WO2019151470A1 (ja) 2019-08-08
ZA202004327B (en) 2022-01-26
PH12020551015A1 (en) 2021-09-06
CA3089952A1 (en) 2019-08-08
EP3747471A1 (en) 2020-12-09
BR112020015567A2 (pt) 2021-02-02
SG11202006255UA (en) 2020-07-29
AU2019214265A1 (en) 2020-07-23
KR20200116953A (ko) 2020-10-13
MX2020007948A (es) 2020-12-10
RU2020128700A (ru) 2022-03-02
EP3747471A4 (en) 2021-10-27

Similar Documents

Publication Publication Date Title
JP2024069363A (ja) 翼状片を治療するための組成物及び方法
CN111683682A (zh) 用于预防或治疗伴有眼内血管新生和/或眼内血管通透性亢进的眼科疾病的药物
JP5314931B2 (ja) 加齢黄斑変性の予防又は治療剤
JP5212849B2 (ja) 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬
WO2010125416A1 (en) Drug delivery to the anterior and posterior segments of the eye
JP7365056B6 (ja) 眼充血を治療するための組成物およびそれを用いて眼充血を治療するための方法
JP2008308489A (ja) ロピニロール又はその塩を有効成分として含有する後眼部疾患の予防又は治療剤
RS63136B9 (sr) Lekoviti sastav koji sadrži tivozanib
US10426783B2 (en) Therapeutic agent for ocular fundus disease
JP5934229B2 (ja) 眼血管疾患の処置のための投与計画
JP6872322B2 (ja) クエン酸エステルを含有するデポ剤
US20230089914A1 (en) Compositions comprising axitinib and methods of treating ocular disorders
CN106604730B (zh) 角膜厚度调节剂
US20230025836A1 (en) Eye drop composition for preventing or treating eye disease
US10537563B2 (en) Methods for treating ocular disease using inhibitors of CSF-1R
WO2010117077A1 (ja) シロリムス誘導体を有効成分として含有する網脈絡膜疾患の治療剤
HK40035073A (en) Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability
CN116515827B (zh) 用于治疗年龄相关性黄斑变性的活性成分、药物组合物和应用
CA2888984A1 (en) Methods for treating eye disorders
JP4922588B2 (ja) 角結膜障害治療剤
WO2025078308A1 (en) Gel formulation for topical ocular use
HK40114204A (zh) 通过靶向过氧化物酶体增殖物激活受体(ppar)信号通路治疗屈光性疾病
JP2009079041A (ja) リチウム塩を有効成分として含有する後眼部疾患の治療又は予防剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40035073

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200918